NCT06194552View on ClinicalTrials.gov

A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 6, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

June 30, 2023

Conditions
Alzheimer Disease
Interventions
DRUG

NTRX-07

Investigational orally administered CB2 agonist

DRUG

Placebo

Matched placebo administered orally

Trial Locations (2)

44040

NeuroTherapia, Gates Mills

Unknown

CRU Early Phase Unit Kistarcsa, Kistarcsa

Sponsors
All Listed Sponsors
collaborator

CRU Early Phase Unit Kistarcsa

UNKNOWN

lead

NeuroTherapia, Inc.

INDUSTRY

NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 | Biotech Hunter | Biotech Hunter